Sign In
Buy AUTL
Autolus Therapeutics Earnings Calls
| Release date | May 14, 2026 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.270 |
| EPS Surprise | 6.90% |
| Revenue estimate | 26.266M |
| Revenue actual | 26.218M |
| Revenue Surprise | -0.183% |
| Release date | Mar 27, 2026 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.340 |
| EPS Surprise | -30.80% |
| Revenue estimate | 23.916M |
| Revenue actual | 24.289M |
| Revenue Surprise | 1.56% |
| Release date | Nov 12, 2025 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.300 |
| EPS Surprise | -30.43% |
| Revenue estimate | 24.406M |
| Revenue actual | 21.194M |
| Revenue Surprise | -13.16% |
| Release date | Aug 12, 2025 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.180 |
| EPS Surprise | 25.00% |
| Revenue estimate | 21.078M |
| Revenue actual | 20.923M |
| Revenue Surprise | -0.737% |
Last 4 Quarters for Autolus Therapeutics
Below you can see how AUTL performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 12, 2025 |
| Price on release | $2.15 |
| EPS estimate | -$0.240 |
| EPS actual | -$0.180 |
| EPS surprise | 25.00% |
| Date | Price |
|---|---|
| Aug 06, 2025 | $2.31 |
| Aug 07, 2025 | $2.35 |
| Aug 08, 2025 | $2.33 |
| Aug 11, 2025 | $2.47 |
| Aug 12, 2025 | $2.15 |
| Aug 13, 2025 | $1.84 |
| Aug 14, 2025 | $1.85 |
| Aug 15, 2025 | $1.78 |
| Aug 18, 2025 | $1.88 |
| 4 days before | -6.93% |
| 4 days after | -12.56% |
| On release day | -14.42% |
| Change in period | -18.61% |
| Release date | Nov 12, 2025 |
| Price on release | $1.36 |
| EPS estimate | -$0.230 |
| EPS actual | -$0.300 |
| EPS surprise | -30.43% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $1.36 |
| Nov 07, 2025 | $1.33 |
| Nov 10, 2025 | $1.32 |
| Nov 11, 2025 | $1.50 |
| Nov 12, 2025 | $1.36 |
| Nov 13, 2025 | $1.28 |
| Nov 14, 2025 | $1.37 |
| Nov 17, 2025 | $1.34 |
| Nov 18, 2025 | $1.29 |
| 4 days before | 0% |
| 4 days after | -5.15% |
| On release day | -5.88% |
| Change in period | -5.15% |
| Release date | Mar 27, 2026 |
| Price on release | $1.21 |
| EPS estimate | -$0.260 |
| EPS actual | -$0.340 |
| EPS surprise | -30.80% |
| Date | Price |
|---|---|
| Mar 23, 2026 | $1.40 |
| Mar 24, 2026 | $1.32 |
| Mar 25, 2026 | $1.33 |
| Mar 26, 2026 | $1.29 |
| Mar 27, 2026 | $1.21 |
| Mar 30, 2026 | $1.27 |
| Mar 31, 2026 | $1.38 |
| Apr 01, 2026 | $1.38 |
| Apr 02, 2026 | $1.41 |
| 4 days before | -13.57% |
| 4 days after | 16.53% |
| On release day | 4.96% |
| Change in period | 0.714% |
| Release date | May 14, 2026 |
| Price on release | $1.59 |
| EPS estimate | -$0.290 |
| EPS actual | -$0.270 |
| EPS surprise | 6.90% |
| Date | Price |
|---|---|
| May 08, 2026 | $1.57 |
| May 11, 2026 | $1.58 |
| May 12, 2026 | $1.60 |
| May 13, 2026 | $1.71 |
| May 14, 2026 | $1.59 |
| May 15, 2026 | $1.63 |
| May 18, 2026 | $1.80 |
| May 19, 2026 | $1.63 |
| May 20, 2026 | $1.62 |
| 4 days before | 1.27% |
| 4 days after | 1.89% |
| On release day | 2.52% |
| Change in period | 3.18% |
Autolus Therapeutics Earnings Call Transcript Summary of Q1 2026
Autolus reported strong early commercial traction for AUCATZYL in Q1 2026 with $26.2M net product revenue (up from $9M YoY), initial U.K. launch activity (10+ centers active), and ~73 U.S. centers (targeting >80 by year-end). The company achieved positive gross margin for the first time in Q1 and reiterated full-year 2026 revenue guidance of $120M–$135M. Operational efficiency initiatives, including a 13% workforce reduction and manufacturing optimizations, are expected to double product output year-over-year while holding staffing at or below prior-year levels; those measures are projected to yield ~$15M of annualized savings in 2027. R&D spend declined YoY as certain development and capacity mobilization costs wind down; important clinical milestones include CARLYSLE follow-up, BOBCAT (progressive MS) initial data, and ALARIC (amyloidosis) initial data by year-end, with pediatric obe-cel and LUMINA (lupus nephritis) readouts in 2027–2028. Cash, cash equivalents and marketable securities were $229.4M at 3/31/26, and management expects current resources to fund operations into Q4 2027. The company expects the ALL business to reach positive gross profit at peak (~65%–70%) and to be EBITDA-profitable at the ALL-business level by 2028, while corporate profitability will depend on reinvestment choices.
